First Time Loading...

Valeo Pharma Inc
TSX:VPH

Watchlist Manager
Valeo Pharma Inc Logo
Valeo Pharma Inc
TSX:VPH
Watchlist
Price: 0.11 CAD -8.33% Market Closed
Updated: Apr 23, 2024

Intrinsic Value

VPH's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Valeo Pharma, Inc. engages in the acquisitions, in-licensing or similar arrangements of patent protected, pharmaceutical products in specific therapeutic areas for the Canadian market. [ Read More ]

The intrinsic value of one VPH stock under the Base Case scenario is 0.91 CAD. Compared to the current market price of 0.11 CAD, Valeo Pharma Inc is Undervalued by 88%.

Key Points:
VPH Intrinsic Value
Base Case
0.91 CAD
Undervaluation 88%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Valeo Pharma Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling VPH stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Valeo Pharma Inc

Provide an overview of the primary business activities
of Valeo Pharma Inc.

What unique competitive advantages
does Valeo Pharma Inc hold over its rivals?

What risks and challenges
does Valeo Pharma Inc face in the near future?

Summarize the latest earnings call
of Valeo Pharma Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Valeo Pharma Inc.

Provide P/S
for Valeo Pharma Inc.

Provide P/E
for Valeo Pharma Inc.

Provide P/OCF
for Valeo Pharma Inc.

Provide P/FCFE
for Valeo Pharma Inc.

Provide P/B
for Valeo Pharma Inc.

Provide EV/S
for Valeo Pharma Inc.

Provide EV/GP
for Valeo Pharma Inc.

Provide EV/EBITDA
for Valeo Pharma Inc.

Provide EV/EBIT
for Valeo Pharma Inc.

Provide EV/OCF
for Valeo Pharma Inc.

Provide EV/FCFF
for Valeo Pharma Inc.

Provide EV/IC
for Valeo Pharma Inc.

Show me price targets
for Valeo Pharma Inc made by professional analysts.

What are the Revenue projections
for Valeo Pharma Inc?

How accurate were the past Revenue estimates
for Valeo Pharma Inc?

What are the Net Income projections
for Valeo Pharma Inc?

How accurate were the past Net Income estimates
for Valeo Pharma Inc?

What are the EPS projections
for Valeo Pharma Inc?

How accurate were the past EPS estimates
for Valeo Pharma Inc?

What are the EBIT projections
for Valeo Pharma Inc?

How accurate were the past EBIT estimates
for Valeo Pharma Inc?

Compare the revenue forecasts
for Valeo Pharma Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Valeo Pharma Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Valeo Pharma Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Valeo Pharma Inc compared to its peers.

Compare the P/E ratios
of Valeo Pharma Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Valeo Pharma Inc with its peers.

Analyze the financial leverage
of Valeo Pharma Inc compared to its main competitors.

Show all profitability ratios
for Valeo Pharma Inc.

Provide ROE
for Valeo Pharma Inc.

Provide ROA
for Valeo Pharma Inc.

Provide ROIC
for Valeo Pharma Inc.

Provide ROCE
for Valeo Pharma Inc.

Provide Gross Margin
for Valeo Pharma Inc.

Provide Operating Margin
for Valeo Pharma Inc.

Provide Net Margin
for Valeo Pharma Inc.

Provide FCF Margin
for Valeo Pharma Inc.

Show all solvency ratios
for Valeo Pharma Inc.

Provide D/E Ratio
for Valeo Pharma Inc.

Provide D/A Ratio
for Valeo Pharma Inc.

Provide Interest Coverage Ratio
for Valeo Pharma Inc.

Provide Altman Z-Score Ratio
for Valeo Pharma Inc.

Provide Quick Ratio
for Valeo Pharma Inc.

Provide Current Ratio
for Valeo Pharma Inc.

Provide Cash Ratio
for Valeo Pharma Inc.

What is the historical Revenue growth
over the last 5 years for Valeo Pharma Inc?

What is the historical Net Income growth
over the last 5 years for Valeo Pharma Inc?

What is the current Free Cash Flow
of Valeo Pharma Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Valeo Pharma Inc.

Financials

Balance Sheet Decomposition
Valeo Pharma Inc

Current Assets 25m
Cash & Short-Term Investments 9.6m
Receivables 5.1m
Other Current Assets 10.3m
Non-Current Assets 15.3m
PP&E 2.6m
Intangibles 12.7m
Current Liabilities 51.6m
Accounts Payable 15.8m
Short-Term Debt 26.4m
Other Current Liabilities 9.4m
Non-Current Liabilities 35.8m
Long-Term Debt 35m
Other Non-Current Liabilities 777k
Efficiency

Earnings Waterfall
Valeo Pharma Inc

Revenue
54.3m CAD
Cost of Revenue
-42.7m CAD
Gross Profit
11.6m CAD
Operating Expenses
-29.8m CAD
Operating Income
-18.2m CAD
Other Expenses
-10.2m CAD
Net Income
-28.4m CAD

Free Cash Flow Analysis
Valeo Pharma Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

VPH Profitability Score
Profitability Due Diligence

Valeo Pharma Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Exceptional ROE
Exceptional 1-Year Revenue Growth
Positive Gross Profit
Positive 3-Year Average ROE
36/100
Profitability
Score

Valeo Pharma Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

VPH Solvency Score
Solvency Due Diligence

Valeo Pharma Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Positive Net Debt
34/100
Solvency
Score

Valeo Pharma Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VPH Price Targets Summary
Valeo Pharma Inc

Wall Street analysts forecast VPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VPH is 0.51 CAD with a low forecast of 0.4 CAD and a high forecast of 0.63 CAD.

Lowest
Price Target
0.4 CAD
267% Upside
Average
Price Target
0.51 CAD
364% Upside
Highest
Price Target
0.63 CAD
473% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

VPH Price
Valeo Pharma Inc

1M 1M
-35%
6M 6M
-29%
1Y 1Y
-78%
3Y 3Y
-90%
5Y 5Y
-86%
10Y 10Y
-83%
Annual Price Range
0.11
52w Low
0.11
52w High
0.51
Price Metrics
Average Annual Return 17.44%
Standard Deviation of Annual Returns 104.5%
Max Drawdown -94%
Shares Statistics
Market Capitalization 10.9m CAD
Shares Outstanding 98 657 400
Percentage of Shares Shorted
N/A

VPH Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Valeo Pharma Inc Logo
Valeo Pharma Inc

Country

Canada

Industry

N/A

Market Cap

10.9m CAD

Dividend Yield

0%

Description

Valeo Pharma, Inc. engages in the acquisitions, in-licensing or similar arrangements of patent protected, pharmaceutical products in specific therapeutic areas for the Canadian market. The company is headquartered in Kirkland, Quebec and currently employs 100 full-time employees. The company went IPO on 2019-02-20. The firm acquires or in-licenses brand and hospital specialty products for sale in Canada. The firm is focused on four therapeutic areas, which includes respiratory, oncology, specialty products and neurology. Its respiratory product is Enerzair breezhaler and Atectura breezhaler; its oncology product is Yondelis; its specialty product includes Redesca, Ametop Gel, and M-Eslon and its neurology product is Onstryv. The firm has eight marketed brands and four additional products. Its wholly owned subsidiary is VPI Pharmaceuticals Inc.(VPI).

Contact

QUEBEC
Kirkland
16667 Hymus Blvd
+15146938832.0
http://www.valeopharma.com/

IPO

2019-02-20

Employees

100

Officers

Vice Chairman, President & CEO
Mr. Steven Saviuk CA
Chief Financial Officer
Mr. Pascal Tougas
Director of Communications & Investor Relations
Mr. Frederic Dumais
VP of Legal Affairs & Corporate Secretary
Mr. Guy-Paul Allard
Senior VP & Chief Commercial Officer
Mr. Kyle Steiger
Head of Ophthalmology Business Unit
Mr. Jean Francois Fournier

See Also

Discover More
What is the Intrinsic Value of one VPH stock?

The intrinsic value of one VPH stock under the Base Case scenario is 0.91 CAD.

Is VPH stock undervalued or overvalued?

Compared to the current market price of 0.11 CAD, Valeo Pharma Inc is Undervalued by 88%.